Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Assessment of complete pathologic response after neoadjuvant immunotherapy for MSI-H gastrointestinal cancers.
Authors
Kruti Bhagirath Vora
Massachusetts General Hospital, Boston, MA;
Kruti Bhagirath Vora , Ben Ouyang , Leon Pappas , Kerry Lynn Reynolds , Matthew Strickland , Jill N. Allen , Colin D. Weekes , Ryan Bruce Corcoran , Lawrence Scott Blaszkowsky , David P. Ryan , Joseph Wang Franses , Sakti Chakrabarti , Samuel J Klempner , Aparna Raj Parikh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 43)
DOI
10.1200/JCO.2023.41.4_suppl.43
Abstract #
43
Poster Bd #
B18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
First Author: Robert L. Ferris
Poster
2023 ASCO Annual Meeting
Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.
First Author: Lisanne P. Zijlker
Poster
2023 ASCO Annual Meeting
Immunotherapy for localized MSI-H colorectal cancer: Characterizing endoscopic and imaging response.
First Author: Daniel Aaron Fox
Poster
2023 ASCO Annual Meeting
Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma.
First Author: Antonio D'Alessio